- The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25 million shares, closed regular trading session at $71.48.
- The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ (NASDAQ:IKT) Investigational New Drug (IND) application and issued a Study May Procced (SMP) letter for its drug candidate IkT-001Pro in the treatment of Chronic Myelogenous Leukemia (CML). Inhibikase shares traded as high as 25 percent, in a range of $0.88 to $1.10 on day volume of 8.93 million shares versus three months average volume of 130.03 thousand shares, closed regular trading session at $0.96.
- The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Novavax’s (NASDAQ:NVAX) lead asset Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. Novavax shares traded as high as 1.5 percent, in a range of $34.77 to $37.81 on day volume of 2.8 million shares, closed regular trading session at $35.20.
- Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced they have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. This application follows guidance from the EMA and International Coalition of Medicines Regulatory Authorities (ICMRA) to work towards introducing Omicron-adapted bivalent vaccines. Pfizer shares traded in a range of $46.7 to $47.96 on day volume of 16.47 million shares, closed regular trading session at $46.82.
- BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that its lead asset BCX9930 has demonstrated >99 percent suppression of the alternative pathway (AP), and that >98 percent suppression was maintained for 24 hours post-dosing, in patients with C3 glomerulopathy (C3G), a rare renal disease that is characterized by dysregulation of the AP of the complement system. BioCryst shares traded as high as 1.15 percent, in a range of $14.24 to $14.96 on day volume of 1.97 million shares, closed regular trading session at $14.26.
- FibroGen (NASDAQ:FGEN) has completed patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS). FibroGen shares traded, in a range of $13.04 to $13.6 on day volume of 595.72 thousand shares, closed regular trading session at $13.25.
- 89bio (NASDAQ:ETNB) announced the presentation of data from ENTRIGUE, its Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia (SHTG) at the European Society of Cardiology (ESC) Congress 2022. 89bio shares traded as high as 11.84 percent, in a range of $4.8 to $5.29 on day volume of 874.42 thousand shares, closed regular trading session at $4.95. The company shares traded at $5.09, up 2.83 percent in the after-hours trading session.
- Biomea Fusion (NASDAQ:BMEA) announced presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting, which took place August 25-27, 2022 in Los Angeles, California. The clinical data demonstrate the novel and robust anti-tumor activity of BMF-219 in HGBCL and MM preclinical models that represent categories of high unmet need. Biomea shares traded as high as 1.28 percent, in a range of $12.01 to $12.67 on day volume of 77.33 thousand shares, closed regular trading session at $12.24.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks